Recombinant Human Erythropoietin Beta

Recombinant Human Erythropoietin Beta, often abbreviated as rHuEPO-beta, is a bioengineered version of a natural hormone, Erythropoietin (EPO). This hormone is primarily produced in the kidneys and stimulates the production of red blood cells in the bone marrow. rHuEPO-beta is used therapeutically to treat conditions like anemia, particularly in patients with chronic kidney disease or undergoing chemotherapy. It works by promoting the proliferation and differentiation of erythroid progenitor cells, thereby increasing the red blood cell count and improving oxygen-carrying capacity of the blood.

CHO suspension cell line adapted to high-density culture (>20x10^6 c/ml), and with rapid growth in serum-free media.
Production process of 5 days and 90 mg/L. Final pure rhEPO yield is 30 mg/L.
QC according to European Pharmacopoeia Monograph.

Recombinant Human Erythropoietin (rhEPO) is produced in ExpiCHO/GS cells, containing the human EPO gene amplified by methionine sulfoxamine (MSX)
selection.
The cells are grown in the serum free chemically defined media in 1L bioreactor’s volume. The production lasts 5 days in a fed-batch mode.
rhEPO is purified by standard chromatographic techniques. The yield is around 30 mg of pure EPO. The quality of the product satisfies European Pharmacopoeia requirements.

Advantages
CHO suspension cell line adapted to high-density culture (>20x10^6 c/ml), and with rapid growth in serum-free media.
Production process of 5 days and 90 mg/L. Final pure rhEPO yield is 30 mg/L.
QC according to European Pharmacopoeia Monograph.

Recombinant Human Erythropoietin Beta is used to treat anemia